Loading…
Development of Th17-associated interstitial kidney inflammation in lupus-prone mice lacking the gene encoding Signal Transduction and Activator of Transcription-1 (STAT-1)
Type I interferon (IFN-I) signaling is a central pathogenic pathway in Systemic Lupus Erythematosus (SLE), and therapeutics targeting IFN-I signaling are in development. Multiple proteins with overlapping function participate in IFN signaling, but the signaling events downstream of receptor engageme...
Saved in:
Published in: | Arthritis & rheumatology (Hoboken, N.J.) N.J.), 2016-05, Vol.68 (5), p.1233-1244 |
---|---|
Main Authors: | , , , , , , , , , , |
Format: | Article |
Language: | English |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Type I interferon (IFN-I) signaling is a central pathogenic pathway in Systemic Lupus Erythematosus (SLE), and therapeutics targeting IFN-I signaling are in development. Multiple proteins with overlapping function participate in IFN signaling, but the signaling events downstream of receptor engagement are unclear. We employed highly-multiplexed assays to characterize autoantibody production, cytokine/chemokine profiles, and Signal Transduction and Activators of Transcription (STAT) phosphorylation to investigate the individual roles of IFNAR2, IRF9 and STAT1 in MRL/
lpr
(
lpr
) mice. Surprisingly, we found that
Stat1
−/−
, but not
Irf9
−/−
or
Ifnar2
−/−
mice, developed interstitial nephritis characterized by infiltration with RORγT
+
lymphocytes, macrophages and eosinophils. Despite pronounced interstitial kidney disease and abnormal kidney function,
Stat1
−/−
mice had decreased proteinuria, glomerulonephritis and autoantibody production. Phospho-specific flow cytometry (phosphoflow) revealed shunting of STAT phosphorylation from STAT1 to STAT3/4. In summary, we describe unique contributions of STAT1 to pathology in different kidney compartments, and provide novel insight into tubulointerstitial nephritis (TIN) a poorly understood complication that predicts end-stage kidney disease in SLE patients. |
---|---|
ISSN: | 2326-5191 2326-5205 |
DOI: | 10.1002/art.39535 |